Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
Q4 2024 vs. Q3 2024
How the institutions holding Revelation Biosciences, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 7 | 10 | +3 |
| Shares | 99.0K | 107.2K | +8.24K (+8.3%) |
| Value | $84.3K | $49.4K | −$34.9K (−41.4%) |
New holders (6)
Institutions that held Revelation Biosciences, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 49,840 | $23.0K | 0.00% |
| Two Sigma Securities, LLC | 29,102 | $13.4K | 0.00% |
| StoneX Group Inc. | 14,137 | $6.52K | 0.00% |
| Geode Capital Management, LLC | 10,964 | $5.05K | 0.00% |
| SBI Securities Co., Ltd. | 301 | $139 | 0.00% |
| Royal Bank of Canada | 100 | $0 | 0.00% |
Sold out (3)
Institutions that held Revelation Biosciences, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Sabby Management, LLC | 42,226 | $36.0K |
| UBS Group AG | 40,945 | $34.9K |
| Susquehanna International Group, LLP | 13,258 | $11.3K |